RU2015105561A - Замещенные гетероазепиноны - Google Patents
Замещенные гетероазепиноны Download PDFInfo
- Publication number
- RU2015105561A RU2015105561A RU2015105561A RU2015105561A RU2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A RU 2015105561 A RU2015105561 A RU 2015105561A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- methyl
- oxo
- aryl
- methylamino
- Prior art date
Links
- -1 C-alkoxy Chemical group 0.000 claims abstract 194
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 57
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 51
- 125000003118 aryl group Chemical group 0.000 claims abstract 47
- 229910052799 carbon Inorganic materials 0.000 claims abstract 40
- 229910052736 halogen Inorganic materials 0.000 claims abstract 32
- 150000002367 halogens Chemical class 0.000 claims abstract 32
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 22
- 125000002252 acyl group Chemical group 0.000 claims abstract 21
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims 110
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 28
- 125000005605 benzo group Chemical group 0.000 claims 24
- 229910005965 SO 2 Inorganic materials 0.000 claims 20
- 229910052794 bromium Inorganic materials 0.000 claims 18
- 229910052801 chlorine Inorganic materials 0.000 claims 18
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 17
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 13
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- VHWJSJBTUWUEAL-UHFFFAOYSA-N propanamide;hydrochloride Chemical compound Cl.CCC(N)=O VHWJSJBTUWUEAL-UHFFFAOYSA-N 0.000 claims 2
- JVSKHEKKOOIUQG-UXCLVXGESA-N (2s)-n-[(2s,3s)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-2-methyl-4-oxo-7-(trifluoromethyl)-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)OC2=CC=C(C(F)(F)F)C=C2N1CC1=C(OC)C=CC2=CC(Br)=CC=C12 JVSKHEKKOOIUQG-UXCLVXGESA-N 0.000 claims 1
- IOHRCWWNKMUJHT-CVDCTZTESA-N (2s)-n-[(3s)-5-[(1-benzyl-2-chloroindol-3-yl)methyl]-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide Chemical compound C([C@@H](C1=O)NC(=O)[C@H](C)NC)OC2=CC=CC=C2N1CC(C1=CC=CC=C11)=C(Cl)N1CC1=CC=CC=C1 IOHRCWWNKMUJHT-CVDCTZTESA-N 0.000 claims 1
- GGXKCOCFMZACLS-QNNMEKCMSA-N (2s)-n-[(3s)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1[C@@H](NC(=O)[C@H](C)NC)COC2=CC=CC=C2N1CC1=C(OC)C=CC2=CC(Br)=CC=C12 GGXKCOCFMZACLS-QNNMEKCMSA-N 0.000 claims 1
- YTKHAOHVHVPIRV-DQFHVVJASA-N (2s)-n-[(3s)-5-[(6-cyclopropyl-2-methoxynaphthalen-1-yl)methyl]-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@@H](C1=O)NC(=O)[C@H](C)NC)OC2=CC=CC=C2N1CC(C1=CC=2)=C(OC)C=CC1=CC=2C1CC1 YTKHAOHVHVPIRV-DQFHVVJASA-N 0.000 claims 1
- HCSLWAKAKAIBTE-ZOEDVAEJSA-N (2s)-n-[(3s)-5-[(7-bromo-3-methoxynaphthalen-2-yl)methyl]-8-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1[C@@H](NC(=O)[C@H](C)NC)COC2=CC(C)=CC=C2N1CC1=CC2=CC(Br)=CC=C2C=C1OC HCSLWAKAKAIBTE-ZOEDVAEJSA-N 0.000 claims 1
- NNTKWKIMKMYXDE-COBSGTNCSA-N (2s)-n-[(3s)-5-[[1-(benzenesulfonyl)-2-chloroindol-3-yl]methyl]-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-2-(methylamino)propanamide;hydrochloride Chemical compound Cl.C([C@@H](C1=O)NC(=O)[C@H](C)NC)OC2=CC=CC=C2N1CC(C1=CC=CC=C11)=C(Cl)N1S(=O)(=O)C1=CC=CC=C1 NNTKWKIMKMYXDE-COBSGTNCSA-N 0.000 claims 1
- QZEFMDYLLZEKEG-XJVRPQCWSA-N (2s,3r)-2-amino-n-[(3s)-5-[(7-bromo-3-methoxynaphthalen-2-yl)methyl]-8-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-3-hydroxybutanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC2=CC=C(Br)C=C2C=C1CN1C2=CC=C(C)C=C2OC[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C1=O QZEFMDYLLZEKEG-XJVRPQCWSA-N 0.000 claims 1
- QZEFMDYLLZEKEG-AMWQFRPASA-N (2s,3s)-2-amino-n-[(3s)-5-[(7-bromo-3-methoxynaphthalen-2-yl)methyl]-8-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-3-hydroxybutanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC2=CC=C(Br)C=C2C=C1CN1C2=CC=C(C)C=C2OC[C@H](NC(=O)[C@@H](N)[C@H](C)O)C1=O QZEFMDYLLZEKEG-AMWQFRPASA-N 0.000 claims 1
- NWZYRRPOEASODK-UHFFFAOYSA-N 1-acetylpiperidine-4-carboxamide Chemical compound CC(=O)N1CCC(C(N)=O)CC1 NWZYRRPOEASODK-UHFFFAOYSA-N 0.000 claims 1
- CJKPKVLFYAXEBS-UHFFFAOYSA-N 2,3,6,7-tetrahydrooxazepine Chemical compound C1CC=CCNO1 CJKPKVLFYAXEBS-UHFFFAOYSA-N 0.000 claims 1
- RCQFDAMHGMCSFG-UHFFFAOYSA-N 2-(4-methylindol-1-yl)benzonitrile Chemical compound C1=CC=2C(C)=CC=CC=2N1C1=CC=CC=C1C#N RCQFDAMHGMCSFG-UHFFFAOYSA-N 0.000 claims 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical class [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- BMBANPOHPFKVTA-UHFFFAOYSA-N benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)C1=CC=CC=C1 BMBANPOHPFKVTA-UHFFFAOYSA-N 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- WAKRDDXHAXBEQA-UHFFFAOYSA-N benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC=C1 WAKRDDXHAXBEQA-UHFFFAOYSA-N 0.000 claims 1
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681337P | 2012-08-09 | 2012-08-09 | |
| US61/681,337 | 2012-08-09 | ||
| PCT/EP2013/066431 WO2014023708A1 (en) | 2012-08-09 | 2013-08-06 | Substituted hetero-azepinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015105561A true RU2015105561A (ru) | 2016-09-27 |
Family
ID=48951449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015105561A RU2015105561A (ru) | 2012-08-09 | 2013-08-06 | Замещенные гетероазепиноны |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9394263B2 (enExample) |
| EP (1) | EP2882725A1 (enExample) |
| JP (1) | JP6266617B2 (enExample) |
| KR (1) | KR20150041647A (enExample) |
| CN (1) | CN104470905B (enExample) |
| BR (1) | BR112015001830A2 (enExample) |
| CA (1) | CA2877048A1 (enExample) |
| MX (1) | MX2015001720A (enExample) |
| RU (1) | RU2015105561A (enExample) |
| WO (1) | WO2014023708A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104470940B (zh) * | 2012-09-19 | 2018-10-16 | 霍夫曼-拉罗奇有限公司 | 2-氧代-2，3，4，5-四氢-1H-苯并[b][1，4]二氮杂*及其治疗癌症的用途 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| MX380753B (es) | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| CN106467521A (zh) * | 2015-08-14 | 2017-03-01 | 陈志龙 | 一类双苯并咪唑吲哚衍生物的两种制备方法 |
| CN106467515B (zh) * | 2015-08-18 | 2019-09-24 | 宁波洞密生物科技有限公司 | 一类6-吡啶苯并咪唑吲哚衍生物及其制备方法与医药领域的应用 |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| EP3831811A4 (en) | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| PE20240819A1 (es) | 2020-12-17 | 2024-04-18 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos |
| EP4291558A1 (en) * | 2021-02-12 | 2023-12-20 | F. Hoffmann-La Roche AG | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| WO2023030295A1 (zh) * | 2021-09-01 | 2023-03-09 | 先声再明医药有限公司 | 泛素特异性蛋白酶1(usp1)抑制剂 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| WO2023150790A2 (en) * | 2022-02-07 | 2023-08-10 | The Wistar Institute Of Anatomy And Biology | Novel and highly selective sars-cov-2 mpro inhibitors |
| IL316935A (en) * | 2022-08-11 | 2025-01-01 | Hoffmann La Roche | TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES |
| PE20251399A1 (es) * | 2022-08-11 | 2025-05-22 | Hoffmann La Roche | Derivados de tetrahidrotiazepina biciclicos |
| JP2025526726A (ja) * | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロアゼピン誘導体 |
| TW202417439A (zh) * | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
| CN119930413B (zh) * | 2025-04-10 | 2025-07-22 | 山东辉璟生物医药科技有限公司 | 一种萘丁美酮-d3的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| EP1831187A1 (en) * | 2004-12-14 | 2007-09-12 | AstraZeneca AB | Novel molecular probes |
| CA2610396A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| WO2007101347A1 (en) * | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| EP1996202A1 (en) * | 2006-03-10 | 2008-12-03 | AstraZeneca AB | Chemical compounds |
| CA2677331A1 (en) * | 2007-02-28 | 2008-09-04 | Merck & Co., Inc. | Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
-
2013
- 2013-08-06 CN CN201380035993.XA patent/CN104470905B/zh not_active Expired - Fee Related
- 2013-08-06 WO PCT/EP2013/066431 patent/WO2014023708A1/en not_active Ceased
- 2013-08-06 US US14/418,383 patent/US9394263B2/en not_active Expired - Fee Related
- 2013-08-06 RU RU2015105561A patent/RU2015105561A/ru not_active Application Discontinuation
- 2013-08-06 EP EP13747659.4A patent/EP2882725A1/en not_active Withdrawn
- 2013-08-06 CA CA2877048A patent/CA2877048A1/en not_active Abandoned
- 2013-08-06 MX MX2015001720A patent/MX2015001720A/es unknown
- 2013-08-06 JP JP2015525858A patent/JP6266617B2/ja not_active Expired - Fee Related
- 2013-08-06 KR KR20157005929A patent/KR20150041647A/ko not_active Withdrawn
- 2013-08-06 BR BR112015001830A patent/BR112015001830A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6266617B2 (ja) | 2018-01-24 |
| KR20150041647A (ko) | 2015-04-16 |
| CN104470905B (zh) | 2017-09-12 |
| WO2014023708A1 (en) | 2014-02-13 |
| BR112015001830A2 (pt) | 2017-07-04 |
| MX2015001720A (es) | 2015-04-14 |
| HK1206740A1 (en) | 2016-01-15 |
| CN104470905A (zh) | 2015-03-25 |
| EP2882725A1 (en) | 2015-06-17 |
| US9394263B2 (en) | 2016-07-19 |
| JP2015528821A (ja) | 2015-10-01 |
| CA2877048A1 (en) | 2014-02-13 |
| US20150361059A1 (en) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015105561A (ru) | Замещенные гетероазепиноны | |
| JP2015528821A5 (enExample) | ||
| ES2675022T3 (es) | Inhibidores de indolamina 2,3-dioxigenasa (IDO) | |
| PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
| CN104203952B (zh) | 咪唑并吡咯烷酮化合物 | |
| ES2617619T3 (es) | Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| EA200601287A1 (ru) | Производные (3-оксо-3,4-дигидрохиноксалин-2-иламино) бензамида и родственные соединения в качестве ингибиторов гликогенфосфорилазы для лечения диабета и ожирения | |
| PE20050020A1 (es) | DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20142216A1 (es) | Inhibidores de indazol de la ruta de senalizacion de wnt y usos terapeuticos de los mismos | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| JP2012520867A5 (enExample) | ||
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| JP2015503507A5 (enExample) | ||
| RU2015112192A (ru) | 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака | |
| PE20140934A1 (es) | Derivados de pirazol | |
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| PE20081351A1 (es) | Derivados de quinazolina como agentes anticancerigenos | |
| NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
| ATE348101T1 (de) | Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion | |
| RU2005117374A (ru) | Индолы, полезные для лечения заболеваний, связанных с андрогеновыми рецепторами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171025 |